Your browser doesn't support javascript.
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz, Robert; Pauli, Daniela; Dargvainiene, Justina; Steinhagen, Katja; Engel, Sarah; Herbst, Victor; Zapf, Dorinja; Krüger, Christina; Sharifzadeh, Shahpour; Schomburg, Benjamin; Leypoldt, Frank; Rupp, Jan; Görg, Siegfried; Junker, Ralf; Wandinger, Klaus-Peter.
  • Markewitz R; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany. Electronic address: Robert.markewitz@uksh.de.
  • Pauli D; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Dargvainiene J; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Steinhagen K; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Engel S; Department of Anesthesiology and Intensive Care, University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
  • Herbst V; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Zapf D; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Krüger C; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Sharifzadeh S; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Schomburg B; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Leypoldt F; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany; Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Rupp J; Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany.
  • Görg S; Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.
  • Junker R; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Wandinger KP; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
Clin Microbiol Infect ; 2021 Sep 20.
Article in English | MEDLINE | ID: covidwho-1415295
ABSTRACT

OBJECTIVES:

To investigate the response of the immune system (and its influencing factors) to vaccination with BNT162b2 or mRNA-1273.

METHODS:

531 vaccinees, recruited from healthcare professionals, donated samples before, in between, and after the administration of the two doses of the vaccine. T- and B-cell responses were examined via interferon-γ (IFN-γ) release assay, and antibodies against different epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (S1 and NCP) were detected via ELISA and surrogate neutralization assay. Results were correlated with influencing factors such as age, sex, prior infection, vaccine received (BNT162b2 or mRNA-1273), and immunosuppression. Furthermore, antinuclear antibodies (ANAs) were measured to screen for autoimmune responses following vaccination with an mRNA vaccine.

RESULTS:

No markers of immunity against SARS-CoV-2 were found before the first vaccination. Two weeks after it, specific responses against SARS-CoV-2 were already measurable (median ± median absolute deviation (MAD) anti-S1 IgG 195.5 ± 172.7 BAU/mL; IgA 6.7 ± 4.9 OD; surrogate neutralization 39 ± 23.7%), and were significantly increased two weeks after the second dose (anti-S1 IgG 3744 ± 2571.4 BAU/mL; IgA 12 ± 0 OD; surrogate neutralization 100 ± 0%, IFN-γ 1897.2 ± 886.7 mIU/mL). Responses were stronger for younger participants (this difference decreasing after the second dose). Further influences were previous infection with SARS-CoV-2 (causing significantly stronger responses after the first dose compared to unexposed individuals (p ≤ 0.0001)) and the vaccine received (significantly stronger reactions for recipients of mRNA-1273 after both doses, p < 0.05-0.0001). Some forms of immunosuppression significantly impeded the immune response to the vaccination (with no observable immune response in three immunosuppressed participants). There was no significant induction of ANAs by the vaccination (no change in qualitative ANA results (p 0.2592) nor ANA titres (p 0.08) from pre-to post-vaccination.

CONCLUSIONS:

Both vaccines elicit strong and specific immune responses against SARS-CoV-2 which become detectable one week (T-cell response) or two weeks (B-cell response) after the first dose.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Qualitative research Language: English Clinical aspect: Prognosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Qualitative research Language: English Clinical aspect: Prognosis Year: 2021
...